Miami-Dade County’s Children’s Hospital, Florida’s Cape Cod Hospital, and Miami- Dade County Hospital are among the top 10 U.S. hospital systems that require the most hospitalization and outpatient treatment of children and young adults with traumatic brain injury (TBI).

In a letter sent to the Centers for Medicare & Medicaid Services (CMS) on Thursday, the hospital and the Miami-dade hospital urged CMS to include TBI in its cost-sharing guidelines.

The letter was sent by the National Alliance of Hospital Directors (NAHB), a nonprofit that represents hospital administrators and other hospital executives.

The NAHB is a trade group representing hospitals, and it is not affiliated with the hospital chains.

According to the NAHB, hospitals spend nearly $500 billion per year on TBI treatment, including $40 billion per day in TBI care, and another $40 million per day for emergency room and intensive care services.

The hospitals and the NAHC wrote that hospitals that do not meet the standards “could be subject to increased payments or fines from the government.”

The hospitals also wrote that “the hospitals are likely to be required to take additional steps to reduce costs to their customers.”

In October, the NAHSB released an updated cost-benefit analysis that included TBI as a cost-effective treatment option.

The hospital association said that while the NABSB report indicated the cost-saving benefits of the treatment are outweighed by the significant adverse effects of TBI, the report also showed that the cost savings can be realized over a longer period of time.

The report also said that a TBI hospital can also help reduce the costs of treating other types of traumatic brain injuries, such as concussions.

TBI can occur in the head, neck, face, upper body, and groin.

The number of TBS patients in the U.K. has nearly doubled over the last five years, with more than 600,000 people reported to have suffered a TBS diagnosis in 2016.

In the U: United Kingdom, TBS is a neurodegenerative disease caused by the degeneration of the nerve cells that transmit signals between neurons.

It affects about 1 percent of people, but as it is more common, it is treated with drugs.

According a recent report by the UCL Institute for Neurology and the University of Liverpool, TBI affects the brain and spinal cord in about one in 200,000 adults and 1 in 5,000 children.

In 2015, the UCD Centre for TBI and its researchers published the results of a meta-analysis on the effects of different treatments on brain injuries and mortality in TBS, including neuroprotective drugs.

The study showed that, among all types of TBT, those who had received neuroprotector treatment were significantly less likely to die from their brain injuries.

The authors also found that those who received TBT-specific treatments were at significantly lower risk of death, although they were more likely to experience symptoms, such a headache, confusion, loss of coordination, and disorientation.

The research also showed there were different types of neuroprotection, including drugs to block seizures and spinal nerves, as well as drugs that can block the growth of nerve cells.

The UCD researchers concluded that “neuroprotective and neuroprotactives appear to be complementary and may be useful in preventing the development of neurological damage and the death of Tbs patients.”

In addition to the UCT and Liverpool study, a recent study from the University College London and Imperial College London also showed a significant decrease in the risk of mortality for patients treated with TBI-specific drugs in TBT patients.

Researchers found that the use of TBBT, an anti-neuroinflammatory drug, reduced the risk for death by 42 percent and improved the quality of life by 43 percent.

According the U-K: TBBTs also had a greater impact on cognition than TBB drugs, but it was unclear whether TBB therapies would have such a benefit.

The researchers, who analyzed data from the United Kingdom and the United States, found that patients treated by TBB treatments were more than twice as likely to develop TBS symptoms and experience a more severe TBS-specific disease.

They also found higher levels of cognitive impairment and dementia in the TBS group compared to the control group.

In addition, there was a higher incidence of dementia and cognitive impairment in the group treated with anti-Neurotoxin-1-based TBT drugs compared to those who did not receive anti-TBBT drugs.

“There is a clear need for improved understanding of the neuroproticial effects of the combination of anti-toxins, anti-epileptics and anti-inflammatories used in treating TBS,” the researchers wrote.

The National Institutes of Health (NIH